Bioventus has transformed from a leveraged acquisition casualty into a cash-generating, high-margin medtech turnaround with visible deleveraging, accelerating earnings, and substantial valuation upside.
Overview
Bioventus is a high-conviction medtech turnaround. After debt-funded acquisitions pushed leverage near distress levels, new leadership divested the lower-margin Advanced Rehabilitation business and refocused on pain, surgical, and restorative therapies. Q1 FY2026 validated the reset: sales rose 6.6%, adjusted EPS beat consensus by 52%, adjusted EBITDA rose 24.5%, operating cash flow swung positive, and debt was aggressively prepaid. Guidance was raised, leverage is nearing sub-2.0x, and the company now offers improving growth, margins, cash generation, and balance-sheet optionality.